Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype.

Journal Article (Journal Article)

Codeine is bioactivated to morphine, a strong opioid agonist, by the hepatic cytochrome P450 2D6 (CYP2D6); hence, the efficacy and safety of codeine as an analgesic are governed by CYP2D6 polymorphisms. Codeine has little therapeutic effect in patients who are CYP2D6 poor metabolizers, whereas the risk of morphine toxicity is higher in ultrarapid metabolizers. The purpose of this guideline (periodically updated at http://www.pharmgkb.org) is to provide information relating to the interpretation of CYP2D6 genotype test results to guide the dosing of codeine.

Full Text

Duke Authors

Cited Authors

  • Crews, KR; Gaedigk, A; Dunnenberger, HM; Klein, TE; Shen, DD; Callaghan, JT; Kharasch, ED; Skaar, TC; Clinical Pharmacogenetics Implementation Consortium,

Published Date

  • February 2012

Published In

Volume / Issue

  • 91 / 2

Start / End Page

  • 321 - 326

PubMed ID

  • 22205192

Pubmed Central ID

  • PMC3289963

Electronic International Standard Serial Number (EISSN)

  • 1532-6535

Digital Object Identifier (DOI)

  • 10.1038/clpt.2011.287

Language

  • eng

Conference Location

  • United States